VIBATIV® targets hospital acquired pneumonia from MRSA across Europe
Clinigen Group plc announced that the new first-in-class bactericidal, once-daily, injectable lipoglycopeptide antibiotic VIBATIV® (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia – HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Infectious Disease antibiotic HAP Latest News mrsa telavancin Source Type: news
More News: Drugs & Pharmacology | Hospitals | Infectious Diseases | MRSA | Pneumonia | Staphylococcus Aureus | Superbugs